Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jianzhi Pang
Observed name:
J L Pang
Institutions:
Guilin Medical University,
Chinese PLA General Hospital,
Health Commission of Guangxi Zhuang Autonomous Region
Observed institutions:
Guilin Medical University,
Chinese PLA General Hospital,
Chinese People's Liberation Army,
Health Commission of Guangxi Zhuang Autonomous Region
ORCID:
0009-0003-9915-6522
Observed ORCID:
0009-0003-9915-6522
OpenAlex ID:
A5054372243
Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
2023
·
Xiujuan Chang
, Shumin Yu
, et al.
·
Journal of Hepatocellular Carcinoma
·
3
PDF
[The application of next-generation sequencing in the diagnosis of Pneumocystis pneumonia in non-HIV infected patients].
2020
·
W Zhang
, D Y She
, et al.
·
PubMed
·
2
The best benefit population treated with lenvatinib plus anti-PD-1 for unresectable hepatocellular carcinoma.
2022
·
Xiujuan Chang
, Shumin Yu
, et al.
·
Journal of Clinical Oncology
·
1
Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma: Updated results.
2026
·
Xiujuan Chang
, Hu Li
, et al.
·
Journal of Clinical Oncology
Explainable prediction of MDR/RR-TB in tuberculosis-diabetes mellitus multimorbidity: a machine learning model developed and validated in a dual-center study
2026
·
Xinxin Zhong
, Kuan Liu
, et al.
·
BMC Infectious Diseases
Phase II clinical study of the efficacy and safety of adebrelimab in combination with lenvatinib as second-line treatment for advanced intrahepatic cholangiocarcinoma.
2025
·
Chang Xiu Juan
, Di Wang
, et al.
·
Journal of Clinical Oncology
PDF
Show more works
View as search
Works count:
6
Citation count:
6
H-index:
2
I10-index:
Year
Topic
Type